Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Aerovate Therapeutics Inc
NASDAQ AVTE
Data sourced from
and
and
Aerovate Therapeutics Inc Gross Profit Per Share for the Trailing 12 Months (TTM) ending March 31, 2024: -0.00
Aerovate Therapeutics Inc Gross Profit Per Share is -0.00 for the Trailing 12 Months (TTM) ending March 31, 2024. Gross Profit per Share represents the gross profit allocated to each outstanding share of common stock. It provides insight into the per-share value of gross profit and is commonly used in valuation analysis. A higher value suggests a potentially more favorable investment opportunity.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: AVTE
| CEO | Mr. Timothy P. Noyes M.B.A. |
| IPO Date | June 30, 2021 |
| Location | United States |
| Headquarters | 930 Winter Street, Waltham, MA, United States, 02116 |
| Employees | 51 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Key trends
Similar companies
Adagene Inc
NA
NA
Acrivon Therapeutics Inc. Common Stock
NA
NA
AN2 Therapeutics Inc
NA
NA
Anebulo Pharmaceuticals Inc
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email